Tirofiban for Patients Treated With Alteplase "MR TEA"

Not yet recruiting

Phase 2/3 Results N/A

Summary of Purpose

After intravenous thrombolysis, the overall recanalization rate is 46%, and recclusion after initial recanalization occurs in 14-34%. In the MR TEA, the investigators compared the effects of administration of tirofiban in acute ischemic stroke patients treated with intravenous alteplase thrombolysis with alteplase alone.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 5 December 2017.

6 Dec 2017 23 Nov 2017 1 Dec 2018 31 Mar 2019 1 Dec 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

Not available

Contacts